A lab technician in Singapore performs quality control checks on a biodegradable stent, which is inserted into constricted coronary arteries to help keep them open and normalise blood flow during the treatment heart ailments, September 18, 2008. Singapore-based medical technology firm Biosensors International expects product revenue to grow from $38.7 million in the past fiscal year to $65 to $75 million this fiscal year ending March 2009, from sales of its new heart stent. This excludes sales in China, where Biosensors expects a bid to acquire the remaining 50 percent stake in JW Medical Systems to fail because of Chinese anti-trust laws, said President R. Michael Kleine. REUTERS/Vivek Prakash (SINGAPORE)
REUTERS/VIVEK PRAKASH